Pharmaceuticals

Prostate Cancer Therapeutics Market Forecast 2025–2034: Where Businesses Should Invest Next

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Prostate Cancer Therapeutics Market By 2029?

The prostate cancer therapeutics market has seen strong growth in recent years. It is anticipated to increase from $11.92 billion in 2024 to $12.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.0%. This historical growth can be linked to factors like the rising global occurrence of prostate cancer, increased awareness regarding early cancer screening and diagnosis programs, an expanding elderly male population, and a growing desire for personalized and targeted therapies.

The prostate cancer therapeutics market is projected to experience substantial expansion over the coming years. This market is predicted to reach “$17.77 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth throughout the forecast period include increasing healthcare spending in developing nations, a surge in investments directed towards oncology medications, broader access to sophisticated imaging and diagnostic equipment, and a greater uptake of less invasive and non-surgical therapeutic approaches. Key trends anticipated during the forecast timeframe encompass improvements in targeted cancer interventions, the incorporation of precision cancer medicine, innovative diagnostic imaging instruments propelled by technology, progress in radioligand-based therapeutic options, and breakthroughs in immunotherapy specifically for prostate cancer.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

Which Major Market Drivers Are Shaping The Future Of The Prostate Cancer Therapeutics Market?

The increasing occurrence of prostate cancer is anticipated to drive the expansion of the prostate cancer therapeutics market in the future. Prostate cancer is characterized by the formation of malignant cells within the prostate gland’s tissues, typically impacting older men. The rise in prostate cancer cases is attributed to an aging global population, as the likelihood of developing the condition substantially increases with age, and extended life expectancies mean more men live long enough to develop it. Prostate cancer therapeutics assist in managing the disease by targeting cancerous cells, slowing its progression, and enhancing patients’ quality of life through various treatments such as surgery, radiation, hormone therapy, and newer modalities like immunotherapy. For example, in October 2024, the National Health Service, a UK-based government department, reported that overall cancer diagnoses among men saw a 7% increase in 2022, climbing from 167,917 to 180,877 cases. This growth was largely propelled by a significant surge in prostate cancer cases, which escalated by over 25% to 54,732. Thus, the growing incidence of prostate cancer is fueling the growth of the prostate cancer therapeutics market.

Which Key Segments Fueling The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Sales

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine-Based Therapies

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy, Tyrosine Kinase Inhibitors

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

What Are The Major Trends Driving The Growth Of The Prostate Cancer Therapeutics Market?

Companies operating in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as an oral once-a-day pill for advanced prostate cancer, to enhance patient adherence and overall therapeutic results. This daily oral medication for advanced prostate cancer involves treatments taken daily to manage metastatic castration-resistant prostate cancer by inhibiting testosterone’s impact on cancer cells. For example, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, India’s first oral once-a-day pill containing relugolix, intended for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies works by rapidly suppressing testosterone, which aids in controlling cancer growth and provides an improved cardiovascular safety profile. As an oral therapy, it removes the requirement for injectable treatments that necessitate administration by healthcare providers, thereby offering greater patient convenience. This launch signifies a substantial progression in prostate cancer management within India, offering patients and doctors a new, convenient, safe, and cost-effective treatment option.

Which Key Market Players Are Investing In Expansion And Innovation Of Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol‑Myers Squibb Company, F. Hoffmann‑La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Fusion Pharmaceuticals Inc., Ferring B.V., Tolmar Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Prostate Cancer Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2025, By The Business Research Company

Prostate Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Prostate Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Thyroid Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795